Disease Landscape and Forecast Insights

NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…

MARKET OUTLOOK Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from…

Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-…

Obesity is a significant public health concern in the United States and Europe. Its chronic progression is associated with type 2 diabetes and adverse cardiovascular (CV) health. Following a series…

MARKET OUTLOOK Giant cell arteritis (GCA) is an autoimmune disease marked by inflammation of blood vessels in the head and neck, leading to persistent headaches, flu-like symptoms, and risk of…

Atherosclerotic cardiovascular disease (ASCVD) broadly covers coronary artery disease, including acute coronary syndrome, a history of myocardial infarction, stable or unstable angina, as well as…

Although Ofev and Esbriet are welcome options in the treatment armamentarium for idiopathic pulmonary fibrosis (IPF), therapies that can further delay or reverse disease progression, preserve lung…

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…

Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and even though our understanding of the disease’s…

Renal inflammation associated with SLE, also known as LN, is among the most serious manifestations of the disease. Until recently, no therapy was specifically approved for LN. Most treatments are…

Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the preferred treatments for psoriatic arthritis (PsA) following failure of conventional disease-modifying antirheumatic drugs (…

MARKET OUTLOOK QUESTIONS ANSWERED What patient shares do key therapies and brands garner by the line of therapy in newly diagnosed polycythemia vera patients? What are the quarterly trends…